Your browser doesn't support javascript.
loading
The purple toe syndrome in female with Factor V Leiden mutation successfully treated with enoxaparin.
Dulícek, Petr; Bártová, J; Beránek, M; Malý, J; Pecka, M.
Affiliation
  • Dulícek P; Second Department of Internal Medicine, Department of Hematology, University Hospital and Medical Faculty, Hradec Králové, Czech Republic. PetrDulicek@seznam.cz
Clin Appl Thromb Hemost ; 19(1): 100-2, 2013.
Article in En | MEDLINE | ID: mdl-22531482
ABSTRACT
Purple toe syndrome is a rare complication of warfarin therapy. It occurs usually after 3 to 8 weeks of therapy and it is caused by cholesterol emboli from atheromatous plaque. Sudden onset of pain in affected area, typically in toes and feet, is the main characteristic of the syndrome. We describe a case of a 65-year-old female with purple toe syndrome after 6 weeks of warfarin. Indication of warfarin was a proximal deep venous thrombosis, which developed after prolonged immobilization. Factor V (FV) Leiden and persistent high FVIII activity were found as additional eliciting factors for venous thromboembolism. After warfarin withdrawal and enoxaparin treatment, symptoms disappeared promptly but a slight discoloration of the toe persists.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Warfarin / Factor V / Toes / Enoxaparin / Embolism, Cholesterol / Fibrinolytic Agents / Anticoagulants Limits: Aged / Female / Humans Language: En Journal: Clin Appl Thromb Hemost Year: 2013 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Warfarin / Factor V / Toes / Enoxaparin / Embolism, Cholesterol / Fibrinolytic Agents / Anticoagulants Limits: Aged / Female / Humans Language: En Journal: Clin Appl Thromb Hemost Year: 2013 Document type: Article